| Excerpt | Relevance | Reference |
|---|
| "To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells." | 7.80 | Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. ( Abastabar, M; Akbari, A; Amanpour, S; Dehpour, AR; Faghihloo, E; Ghaffari, SH; Ghahremani, MH; Heidari, M; Karimi, A; Khoshzaban, A; Mobini, GR; Muhammadnejad, S; Shidfar, F, 2014) |
| "To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells." | 3.80 | Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. ( Abastabar, M; Akbari, A; Amanpour, S; Dehpour, AR; Faghihloo, E; Ghaffari, SH; Ghahremani, MH; Heidari, M; Karimi, A; Khoshzaban, A; Mobini, GR; Muhammadnejad, S; Shidfar, F, 2014) |